Ebn Sina Medical to distribute BeiGene’s cancer therapies in Qatar

QATAR – Qatar’s healthcare sector is set to benefit from a new strategic partnership between Ebn Sina Medical and BeiGene, with Ebn Sina Medical becoming the local partner and distributor for BeiGene’s range of oncology medicines.

 This collaboration aims to enhance the availability of innovative cancer treatments in Qatar, providing patients and healthcare providers with greater access to cutting-edge therapies.

The agreement was formalized in a ceremony attended by key figures from both organizations.

Dr. Essam Faragalla, General Manager of Ebn Sina Medical, and Mohammed al-Kapany, General Manager for BeiGene’s MENA region, signed the partnership in the presence of Rashid bin Ali al-Mansoori, CEO of Aamal Company, Markus Dannenberger, BeiGene’s Head of Go-To Market Strategy & Commercial Operations for New Markets, and other dignitaries.

Ebn Sina Medical, a subsidiary of Aamal Company, is recognized as a leading supplier of pharmaceuticals, hospital, and healthcare products in Qatar.

With a strong track record of distributing high-quality medicinal products, Ebn Sina Medical serves both public and private healthcare sectors, supporting the country’s ongoing efforts to improve medical care.

BeiGene, on the other hand, is a global oncology company known for its commitment to developing and delivering innovative cancer therapies.

This partnership underscores Ebn Sina Medical’s dedication to advancing healthcare in Qatar.

According to Rashid bin Ali al-Mansoori, the country’s medical sector has seen remarkable progress over the past two decades, with the establishment of world-class healthcare facilities.

He emphasized that the new partnership with BeiGene represents a significant addition to the treatment options available for cancer patients in Qatar.

Al-Mansoori described the collaboration as a “paradigm shift” that will further elevate Qatar’s medical sector by introducing advanced therapies and fostering partnerships with leading international healthcare companies.

He noted that Ebn Sina Medical’s strong market position establishes it as a trusted partner for well-known global pharmaceutical companies such as BeiGene.

Al-Mansoori also expressed his eagerness to see the positive impact this partnership will have on healthcare in Qatar.

Dr. Essam Faragalla echoed these sentiments, describing the partnership as an important step in expanding access to advanced oncology treatments within the country.

 He highlighted that the alliance aligns with Ebn Sina Medical’s vision to be an active contributor to Qatar’s healthcare ecosystem by fostering innovation and increasing access to modern therapeutic solutions.

Faragalla stated that their goal is to support healthcare professionals by providing them with the tools necessary to enhance patient care.

“Through strategic collaborations like this, we continue to strengthen the healthcare system and enhance treatment options for patients facing complex health challenges,” He noted.

From BeiGene’s perspective, Mohammed al-Kapany reaffirmed the company’s commitment to expanding access to innovative and affordable cancer treatments worldwide.

He also mentioned that this partnership with Ebn Sina Medical reflects their shared goal of improving outcomes for individuals living with cancer in Qatar

“Together, we’re working to ensure that patients and healthcare providers have access to the high-quality therapies they need—where and when they need them,” he remarked.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.